CognitMarket market news, portfolio research, and investor insights

Peoples Bancorp (PEBO) will acquire Capital Bancorp (CBNK) in an all-stock transaction valued at approximately $728.1 million. Capital shareholders will receive 1.11 shares of PEBO for each CBNK share, valuing CBNK at $43.75 per share based on PEBO's 20-day VWAP 🔗. The deal is expected to be immediately accretive to Peoples' 2027 earnings and create a combined entity with $14 billion in assets. PEBO shares fell 6%, while CBNK surged 11% on the news 🔗.

The biotech sector is experiencing notable volatility following a wave of clinical trial results:

• Candel Therapeutics (CADL): Shares likely to react positively after Phase 3 data showed a 41% reduction in prostate cancer recurrence risk for its drug aglatimagene. BLA submission planned for Q4 2026 🔗.
• Rafael Holdings (RFL): Stock tumbled 25% as its Phase 3 trial for Niemann-Pick Disease Type C missed its primary endpoint, despite showing a statistically significant effect in a prespecified subgroup 🔗.
• Sagimet Biosciences (SGMT): Stock surged over 12% on positive 52-week Phase 3 data for its acne drug denifanstat, showing a 57% treatment success rate. The company also announced a $115M stock offering 🔗.
• Theriva Biologics (TOVX): Results from its Phase 2b pancreatic cancer trial, showing improved overall survival with VCN-01, were published in Nature Medicine 🔗.
• Merck (MRK): Positive Phase 2b data for tulisokibart in hidradenitis suppurativa, meeting primary and key secondary endpoints. These findings will inform Phase 3 development 🔗.
• Eli Lilly (LLY): Ebglyss met primary and secondary endpoints in a Phase 3b trial for hand and foot atopic dermatitis, showing 53% clear/almost clear skin vs. 27% for placebo 🔗.
• Sarepta Therapeutics (SRPT): Presented new functional outcome data for its gene therapy Elevidys in older Duchenne muscular dystrophy patients, showing improved North Star Ambulatory Assessment scores 🔗.

These diverse outcomes highlight the high-stakes nature of clinical development, driving significant stock movements across the industry.

The biotech sector is experiencing significant volatility driven by recent clinical trial data. Candel Therapeutics (CADL) surged on positive Phase 3 data for its prostate cancer drug, showing a 41% reduction in recurrence risk and plans for a Q4 2026 BLA submission 🔗. Similarly, Sagimet Biosciences (SGMT) rose over 12% after positive 52-week results for its acne drug, denifanstat, with a 57% treatment success rate 🔗. Theriva Biologics (TOVX) also announced improved overall survival in pancreatic cancer patients from its VCN-01 trial, published in Nature Medicine 🔗.

Conversely, Rafael Holdings (RFL) shares tumbled 25% as its Phase 3 trial for Niemann-Pick Disease Type C failed to meet its primary endpoint, despite a statistically significant effect in a subgroup 🔗. Merck (MRK) and Eli Lilly (LLY) also reported positive Phase 2b/3b data for their respective drugs in skin diseases, with Merck's tulisokibart meeting primary endpoints in hidradenitis suppurativa 🔗 and Lilly's Ebglyss showing efficacy in hand/foot atopic dermatitis 🔗.

Meta Platforms' (META) new AI agent, Muse, is pressuring online travel agency (OTA) stocks, according to Truist analysts 🔗. Muse's ability to book travel, combined with Meta's consumer reach and data resources, poses significant downside risks to OTAs.

Truist highlights Expedia Group (EXPE) as particularly vulnerable, given Muse's North American launch and Expedia's two-thirds U.S.-based B2C operations. Booking Holdings (BKNG) has lower U.S. exposure. The extent of impact on bookings, commission rates, and competitive positioning remains uncertain, but investor sentiment is likely to be affected 🔗.

Hedge funds now hold a record 7% ($2 trillion) of the $30 trillion US Treasury market, nearly tripling their holdings in five years 🔗. This surge, while helping fund government debt, raises concerns among experts about potential systemic risk due to hedge funds' aggressive leverage 🔗.

Key points:

• Hedge funds' share of marketable Treasury debt reached 7% by end of 2025, continuing to grow in H1 2026 🔗.
• Experts warn that forced deleveraging in extreme situations could lead to broader liquidity and financial stability events 🔗.
• This comes as 10-year and 30-year Treasury yields hit multi-year highs 🔗.

S&P Global Ratings has upgraded Wells Fargo (WFC) long-term issuer credit rating to 'A-' from 'BBB+'. The upgrade reflects significant progress in governance, risk culture, and operational oversight following the termination of its Federal Reserve asset cap. The bank's balance sheet growth has outpaced the sector, with resilient credit performance and strong capital cushions. S&P maintains a stable outlook, expecting continued return improvements while managing risk. 🔗

Cruise operators are sailing higher today after Carnival (CCL) reported better-than-expected Q3 earnings and issued an optimistic outlook. CCL shares jumped 12%, leading gains among rivals Royal Caribbean (RCL) and Norwegian Cruise Line Holdings (NCLH).

Key Highlights:

• CCL adjusted EPS of $1.43 vs. $1.35 est. on $8.44B revenue vs. $8.35B est. 🔗
• Net yields projected up 3.8% in FY2026, above 3.2% consensus 🔗
• Booked occupancy and pricing for 2027 at record levels 🔗

This performance reinforces the sector's recovery trajectory despite macroeconomic headwinds. 🔗

Iovance Biotherapeutics (NASDAQ: IOVA) shares jumped over 14% in premarket trading after the company significantly raised its full-year 2026 revenue outlook to $410M-$420M. This updated forecast, driven by strong adoption of its Amtagvi therapy, exceeds the prior guidance midpoint by $55M and clears consensus analyst estimates of $402.8M 🔗.

Key points:

• Guidance Increase: Midpoint of new guidance ($415M) is 3.0% above consensus.
• Commercial Momentum: Strong domestic adoption of Amtagvi and sustained Proleukin sales cited.
• Expansion: On track to expand authorized treatment centers to 110 by year-end 2026.
• Profitability: Operational efficiencies accelerating timeline toward profitability.

AI lab Anthropic plans to spend at least $518 billion over the next decade on AI infrastructure, with the majority in non-cancelable deals. This massive commitment signals significant future revenue for key tech partners:

• Alphabet (GOOGL): $111.1 billion
• Amazon (AMZN): $110 billion
• Microsoft (MSFT): $31.4 billion
• Broadcom (AVGO): $161.2 billion in equipment lease obligations

The company highlights compute power as the key constraint for AI development, with future demand likely to exceed supply. This underscores the ongoing AI infrastructure buildout and its direct financial impact on major cloud and chip providers. 🔗

The CME Group's FedWatch Tool indicates a significant increase in the probability of further Federal Reserve rate hikes. There's now a 45.9% chance of 50 basis points in hikes and a 25.1% possibility of 75 basis points in hikes by the January 27, 2027 FOMC meeting. This suggests a strong market expectation for aggressive tightening to combat persistent inflation, with President Trump's tariff policies cited as a contributing factor 🔗. This development could signal continued pressure on equities and bonds as borrowing costs rise.